Nalaganje...
Patient and Provider Characteristics Associated With Sodium–Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease
Despite accumulating evidence of cardiorenal benefits from sodium–glucose cotransporter 2 (SGLT2) inhibitors, prescription of agents in this drug class may be limited by concerns regarding adverse effects and interdisciplinary care coordination. To investigate these potential barriers, we performed...
Shranjeno v:
| izdano v: | Clin Diabetes |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Diabetes Association
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7364452/ https://ncbi.nlm.nih.gov/pubmed/32699472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/cd19-0087 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|